natgillin/translations-raw huggingface dataset:
Osteonecrosis of the jaw(ONJ) has been reported very rarely in the post marketing setting in patients receiving ibandronic acid for oncology indications (see section 4.8).
Osteonekroza čeljusti primijećena je vrlo rijetko nakon stavljanja lijeka u promet u bolesnika koji su primali ibandronatnu kiselinu za onkološke indikacije (vidjeti dio 4.8).
Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelitis) has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphosphonates.
Osteonekroza čeljusti, obično povezana s vađenjem zuba i/ili lokalnom infekcijom (uključujući osteomijelitis), primijećena je u bolesnika s rakom čije se liječenje prvenstveno zasnivalo na intravenskoj primjeni bisfosfonata.
Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelitis), has been reported in patients with cancer who are receiving treatment regimens including primarily intravenously administered bisphosphonates.
U bolesnica s karcinomom liječenih uglavnom intravenskom primjenom bisfosfonata prijavljena je osteonekroza čeljusti, u pravilu povezana s vađenjem zuba i/ili lokalnom infekcijom (uključujući osteomijelitis).
Osteonecrosis of the jawa,b
osteonekroza koja ne zahvaća čeljusta,f
osteonecrosis of the jaw‡§; atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction)
osteonekroza čeljusti‡§; netipični subtrohanterični prijelomi i prijelomi dijafize femura (nuspojava skupine bisfosfonata)
Osteonecrosis: Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV–disease and/or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: Iako se smatra da ima više uzroka (uključujući uzimanje kortikosteroida, konzumiranje alkohola, jaku imunosupresiju, povećan indeks tjelesne mase), osteonekroza je prijavljena posebno u bolesnika s uznapredovalom HIV bolešću i/ili u bolesnika na dugotrajnoj kombiniranoj antiretrovirusnoj terapiji (CART).
Osteonecrosis: Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: Premda je etiologija osteonekroze multifaktorijalna (uključujući primjenu kortikosteroida, konzumaciju alkohola, tešku imunosupresiju, viši indeks tjelesne mase), slučajevi osteonekroze prijavljeni su posebno u bolesnika s uznapredovalom HIV bolešću i/ili nakon dugotrajne izloženosti kombiniranoj antiretrovirusnoj terapiji (tzv.
Osteoporosis
epistaksa
Osteoporosis
proteinurija
osteoporosis (bone disease), sickle cell anaemia, as filgrastim may cause sickle cell crisis.
osteoporozu (bolest kostiju), anemiju srpastih stanica, jer filgrastim može uzrokovati krizu srpastih stanica.
osteoporosis (bone disease), sickle cell disease anaemia, as filgrastim can cause sickle cell crisis.
osteoporozu (bolest kostiju), anemiju srpastih stanica jer filgrastim može uzrokovati krizu srpastih stanica.
osteoporosis (bone disease); sickle cell anaemia, as Filgrastim HEXAL may cause sickle cell crisis.
osteoporozu (bolest kostiju); anemiju srpastih stanica jer Filgrastim HEXAL može uzrokovati krizu srpastih stanica.
osteoporosis (bone disease); sickle cell anaemia, as Zarzio may cause sickle cell crisis.
osteoporozu (bolest kostiju); anemiju srpastih stanica jer Zarzio može uzrokovati krizu srpastih stanica.
Osteoporosis/osteopen ia, arthralgia, muscular weakness, muscle spasms, joint swelling/stiffness
osteoporoza/osteopenija, artralgija, mišićna slabost, grčevi mišića, oticanje/ukočenost zglobova
Osteoporosis/osteopenia, arthralgia muscular weakness, muscle spasms, joint swelling/stiffness
osteoporoza/osteopenija, artralgija, mišićna slabost, grčevi mišića, oticanje/ukočenost zglobova
Osteosarcomas, a known effect of bone-seeking radionuclides, were observed at clinically relevant doses in rats 7 – 12 months after start of treatment.
Osteosarkomi, poznati učinak radionuklida koji se nakupljaju u kosti, bili su opaženi pri klinički relevantim dozama u štakora 7-12 mjeseci nakon početka liječenja.
OSURNIA ear gel for dogs
OSURNIA gel za uho za pse
otalol (for heart disorders) ritonavir (anti-HIV medicine). medicines known to affect the way your heart beats (drugs that prolong the QT interval).
otalol (za liječenje srčanih poremećaja) ritonavir (za liječenje HIV infekcije) lijekove koji utječu na način rada srca (lijekovi koji produljuju QT-interval)
Oteracil, gimeracil, 5-FU, and tegafur were 8.4%, 32.2%, 18.4%, and 52.3% protein bound, respectively.
Oteracil, gimeracil, 5-FU i tegafur se vezuju za proteine 8,4 %, 32,2 %, 18,4 % i 52,3 % .
Otezla 10 mg film-coated tablets Otezla 20 mg film-coated tablets Otezla 30 mg film-coated tablets
Otezla 10 mg filmom obložene tablete Otezla 20 mg filmom obložene tablete Otezla 30 mg filmom obložene tablete
Otezla 10 mg tablets Otezla 20 mg tablets Otezla 30 mg tablets
Otezla 10 mg tablete Otezla 20 mg tablete Otezla 30 mg tablete
Otezla 30 mg film–coated tablets apremilast
Otezla 30 mg filmom obložene tablete apremilast
Otezla contains the active substance ‘apremilast’.
Otezla sadrži djelatnu tvar apremilast.
Otezla has no effect on the ability to drive and use machines.
Otezla ne utječe na sposobnost upravljanja vozilima i strojevima.
Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).
Lijek Otezla indiciran je za liječenje umjerene do teške kronične plak psorijaze u odraslih bolesnika u kojih nije bilo odgovora ili im je kontraindicirana ili ne podnose drugu sistemsku terapiju uključujući ciklosporin, metotreksat ili psoralen i ultraljubičasto A svjetlo (PUVA).
Otezla is used to treat adults with the following conditions:
Otezla se koristi za liječenje odraslih sa sljedećim stanjima:
Otezla should be dose reduced to 30 mg once daily in patients with severe renal impairment (see sections 4.2 and 5.2).
U bolesnika s teškim oštećenjem funkcije bubrega, dozu lijeka Otezla treba smanjiti na 30 mg jedanput na dan (vidjeti dijelove 4.2 i 5.2).
Otezla works by reducing the activity of an enzyme in the body called ‘phosphodiesterase 4’, which is involved in the process of inflammation.
Otezla djeluje tako da u tijelu smanjuje aktivnost enzima koji se naziva 'fosfodiesteraza 4' a uključen je u upalni proces.
OTFC (normalized to 400 mcg)
OTFC (normalizirano na 400 mikrograma)
OTFC data was dose adjusted (800 mcg to 400 mcg)
OTFC podaci su načinjeni prema prilagodbi doze (800 mikrograma na 400 mikrograma)
Othe r me dicines and Mimpara
Drugi lije kovi i Mimpara
Othe r me dicines and Sabe rvel
Drugih lije kova i Sabe rve l
Othe r me dicines and Sabe rvel
Drugih lije kovi i Sabe rvel
Other
5,2
Other
druga
Other
drugi
Other
Ostali lijekovi
Other
Ostalob
OTHER (FOR CALENDARISED PACKS)
DRUGO (ZA KALENDARSKA PAKIRANJA)
Other (N = 252)
N = 106
Other (N = 252)
velikih stanica
Other 1 0
Ostalo 1 0
Other 4/297 1.3
Ostalo 4/297 1,3
Other acid-lowering medicines like ranitidine and omeprazole can be taken at the same time as Tivicay.
Drugi lijekovi koji smanjuju količinu kiseline u želucu, poput ranitidina i omeprazola, mogu se uzimati istodobno s lijekom Tivicay.
Other acid-lowering medicines like ranitidine and omeprazole can be taken at the same time as Triumeq.
Drugi lijekovi koji smanjuju količinu kiseline u želucu, poput ranitidina i omeprazola, mogu se uzimati istodobno s lijekom Triumeq.
Other activators of the innate immune system, such as endogenous agonists of toll-like receptors, may contribute to the transcriptional activation of the IL- 1 beta gene, initiating a gouty arthritis attack.
Drugi aktivatori prirođenog imunološkog sustava, kao što su endogeni agonisti receptora sličnih Tollu, mogu doprinijeti transkripcijskoj aktivaciji IL-1 beta gena te započeti napad uričnog artritisa.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale djelatne tvari poput cimetidina, ranitidina, prokainamida, kinidina, kinina i nikotina koje koriste isti sustav bubrežnog kationskog transporta kao i amantadin mogle bi također stupiti u interakciju s memantinom i dovesti do potencijalnog rizika povišenja njegove koncentracije u plazmi.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale djelatne tvari poput cimetidina, ranitidina, prokainamida, kinidina, kinina i nikotina koje koriste isti sustav bubrežnog kationskog transporta kao i amantadin mogli bi također stupiti u interakciju s memantinom i dovesti do potencijalnog rizika povišenja njegove koncentracije u plazmi.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale djelatne tvari poput cimetidina, ranitidina, prokainamida, kinidina, kinina i nikotina koje koriste isti sustav bubrežnog kationskog transporta kao i amantadin, mogle bi također stupiti u interakciju s memantinom i dovesti do potencijalnog rizika povišenja njegove koncentracije u plazmi.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale djelatne tvari poput cimetidina, ranitidina, prokainamida, kinidina, kinina i nikotina koje koriste isti sustav bubrežnog kationskog transporta kao i amantadin, mogli bi također stupiti u interakciju s memantinom i dovesti do potencijalnog rizika povišenja njegove koncentracije u plazmi.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine andnicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Ostale djelatne tvari poput cimetidina, ranitidina, prokainamida, kinidina, kinina i nikotina koje koriste isti sustav bubrežnog kationskog transporta kao i amantadin mogle bi također stupiti u interakciju s memantinom i dovesti do potencijalnog rizika povišenja njegove koncentracije u plazmi.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine andnicotine that use the same renal cationic transport system as amantadine may also possiblyi nteract with memantine leading to a potential risk of increased plasma levels.
Ostale djelatne tvari poput cimetidina, ranitidina, prokainamida, kinidina, kinina i nikotina koje koriste isti sustav bubrežnog kationskog transporta kao i amantadin mogle bi također stupiti u interakciju s memantinom i dovesti do potencijalnog rizika povišenja njegove koncentracije u plazmi.
Other adverse drug reactions
Druge nuspojave
Other adverse reactions have been identified during post approval use of NutropinAq.
Nakon odobrenja za stavljanje u promet lijeka NutropinAq utvrđene su i druge nuspojave.
Other agents
Ostali lijekovi
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5,
Ostali aleli povezani sa odsutnim ili smanjenim metabolizmom uključuju CYP2C19*4, *5, *6, *7 i *8, ali oni su manje zastupljeni.
other allergic reactions tiredness
druge alergijske reakcije umor.
Other animals, such as rabbits and small rodents, have not been tested.
Druge životinje, kao i zečevi i mali glodavci nisu još testirani.
Other anti-cancer medicines as they may contribute to the release of too much uric acid when tumour cells are destroyed by asparaginase.
Drugi lijekovi protiv raka mogu pridonijeti oslobađanju prevelike količine uratne kiseline kada su tumorske stanice uništene asparaginazom.
other anti-depressants (such as venlafaxine and tryptophan) used in major depression tricyclic’s (such as clomipramine and amitriptyline) used for depressive illness
drugi antidepresivi (kao što su venlafaksin i triptofan) koji se primjenjuju kod teške depresije
Other anti-epileptic medicines, such as carbamazepine, oxcarbazepine, and phenytoin that are used to treat fits may affect Fycompa.
Drugi antiepileptici, kao što je karbamazepin, okskarbazepin i fenitoin koji se primjenjuju za liječenje napadaja mogu utjecati na Fycompu.
Other Anti-infectives
Ostali antiinfektivi
Other anti-rheumatic therapies have been associated with hepatitis B reactivation.
Druge antireumatske terapije povezane su reaktivacijom hepatitisa B. Stoga prije početka terapije
Other anti-rheumatic therapies have been associated with hepatitis B reactivation.
Druge antireumatske terapije povezane su reaktivacijom hepatitisa B. Stoga, prije početka terapije
Other antiarrhythmic medicinal products had to be withdrawn for at least 5 plasma half-lives prior to the first administration.
Prije prve primjene dronedarona primjenu drugih antiaritmika trebalo je prekinuti tijekom razdoblja koje odgovara razdoblju od najmanje 5 poluvjekova lijeka u plazmi.
Other antidepressants:
Drugi antidepresivi:
Other antihypertensive agents may increase the hypotensive effects of irbesartan; however irbesartan has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Drugi antihipertenzivi mogu pojač ati hipotenzivni uč inak irbesartana; irbesartan se, međ utim, pokazao sigurnim za primjenu s ostalim antihipertenzivnim lijekovima poput beta blokatora, dugodjelujuć ih blokatora kalcijevih kanala i tiazida.
Other antihypertensive agents: The antihypertensive effect of Rasilez HCT may be increased with the concomitant use of other antihypertensive agents.
Drugi antihipertenzivni lijekovi: antihipertenzivni učinak Rasilez HCT-a može se povećati istodobnom primjenom drugih antihipertenzivnih lijekova.
Other antiretroviral agents: no specific recommendation can be made with regard to other available antiretroviral agents due to the lack of data.
Drugi antiretrovirusni lijekovi: zbog nedostatka podataka nema specifične preporuke glede drugih dostupnih antiretrovirusnih lijekova.
Other antiretroviral medicinal products
Drugi antiretrovirusni lijekovi
Other Antiviral agents
Ostali antivirotici
Other associations include rash, bronchospasm, lymphadenopathy, haemolytic anaemia, vasculitis, uveitis, angioedema, agranulocytosis, the sicca syndrome, myalgia, elevation in serum levels of skeletal-muscle enzymes, and pneumonitis.
Druge povezane nuspojave uključuju osip, bronhospazam, limfadenopatiju, hemolitičku anemiju, vaskulitis, uveitis, angioedem, agranulocitozu, sindrom sicca, mialgiju, povišenje serumskih razina koštano-mišićnih enzima i pneumonitis.
Other autoimmune conditions
Ostale autoimune bolesti
Other baseline factors in co-infected patients that may be associated with a higher risk of hepatic decompensation include treatment with didanosine and elevated bilirubin serum concentrations.
Ostali čimbenici prisutni na početku liječenja kod bolesnika s istodobnom infekcijom koji mogu biti povezani s povećanim rizikom od dekompenzacije jetre uključuju liječenje didanozinom i povećanu koncentraciju bilirubina u serumu.
Other binding proteins may be elevated in serum, i.e. corticoid binding globulin (CBG), sex-hormone-binding globulin (SHBG) leading to increased circulating corticosteroids and sex steroids, respectively.
Ostali vezani proteini mogu biti povišeni u serumu, npr. globulin koji veže kortikoide (CBG) i globulin koji veže spolne hormone (SHBG), što dovodi do povećanih razina kortikosteroida odnosno spolnih steroida u cirkulaciji.
Other bleeding events (including events such as epistaxis, post-procedural haemorrhage and haematuria) were reported in 13.3% of patients treated with Jakavi and 10.3% treated with reference treatments.
Ostali događaji krvarenja (uključujući događaje kao što je epistaksa, postproceduralno krvarenje i hematurija) bili su prijavljeni u 13,3% bolesnika liječenih Jakavijem te u 10,3% liječenih referentnim terapijama.
Other bleeding events (including events such as epistaxis, post-procedural haemorrhage, gingival bleeding) were reported in 11.8% of patients treated with Jakavi and 6.3% treated with best available therapy.
Drugi događaji krvarenja (uključujući događaje kao što su epistaksa, postproceduralno krvarenje, gingivalno krvarenje) bili su zabilježeni u 11,8% bolesnika liječenih Jakavijem te u 6,3% liječenih najboljom dostupnom terapijom.
Other bronchodilators (such as salbutamol).
ostale bronhodilatatore (poput salbutamola).
Other Candida spp.
Candida spp.- ostali
Other Candida spp.2
druge Candida spp.2
Other cases in which Holoclar cannot be used
Drugi slučajevi u kojima se ne može primijeniti Holoclar
Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with Kentera.
Ostali uzroci čestog mokrenja (zatajenje srca ili bubrežna bolest) trebaju biti utvrđeni prije početka liječenja Kenterom.
other central nervous system depressants, other opioid derivatives (e.g. methadone, analgesics and antitussives), certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, neuroleptics, clonidine and related substances: these combinations increase central nervous system depression.
drugim depresorima središnjeg živčanog sustava, drugim derivatima opioida (npr. metadon, analgetici i antitusici), određenim antidepresivima, sedativnim antagonistima H1-receptora, barbituratima, drugim anksioliticima koji nisu benzodiazepini, neurolepticima, klonidinom i klonidinu sličnim tvarima: ove kombinacije povećavaju depresiju središnjeg živčanog sustava.
Other changes in blood biochemical and haematological parameters probably associated with the use of prednisolone were significant effects noticed on lactate dehydrogenase (decrease) and abumin (increase) and on eosinophils, lymphocytes (decrease) and segmented neutrophils (increase).
Druge promjene u biomehaničkh i hematoloških parametara krvi, koji su vjerojatno povezani s primjenom prednizolona, bile su značajni učinci uočeni u dehidrogenazi laktata (smanjenje) i albumina (povećanje), te u eozinofilima, limfocitima (smanjenje) i segmentiranim neutrofilima (povećanje).
Other changes in blood biochemical and haematological parameters probably associated with the use of prednisolone were significant effects noticed on lactate dehydrogenase (decrease) and albumin (increase) and on eosinophils, lymphocytes (decrease) and segmented neutrophils (increase).
Druge promjene biomehaničkih i hematoloških parametara krvi, koje su vjerojatno povezane s primjenom prednizolona, bile su značajni učinci uočeni u dehidrogenazi laktata (smanjenje) i albumina (povećanje), te u eozinofilima, limfocitima (smanjenje) i segmentiranim neutrofilima (povećanje).
Other clinical experience has not identified differences in responses between the older and younger patients (see section 5.2).
Ostalo kliničko iskustvo nije pokazalo razlike u odgovoru na liječenje između starijih i mlađih bolesnika (vidjeti dio 5.2).
Other clinically
Druge klinički
Other clinically relevant severe side effectswere diabetes (common) and inflammation of the pancreas (uncommon).
Ostale klinički značajne teške nuspojave bile su šećerna bolest (često) i upala gušterače (manje često).
Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorder, mania, confusion and alterations of mental status have been observed with alpha interferons.
U bolesnika liječenih alfa interferonima opaženi su drugi učinci na SŽS, uključujući agresivno ponašanje (ponekad usmjereno protiv drugih, poput homicidalnih ideja), bipolarni poremećaj, manija, smetenost i promjene mentalnog statusa.
Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorder, mania,), confusion and alterations of mental status have been observed with alpha interferons.
U bolesnika liječenih alfa interferonima opaženi su drugi učinci na SŽS, uključujući agresivno ponašanje (ponekad usmjereno protiv drugih, poput homicidalnih ideja), bipolarni poremećaj, manija, smetenost i promjene mentalnog statusa.
OTHER CODDITIONS AND REQUIREMENT OF THE MARKETING AUTHORISATION
OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
Other combinations
Druge kombinacije
OTHER COMDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
OSTALI UVJETI I ZAHTJEVI ZA STAVLJANJE GOTOVOG LIJEKA U PROMET
Other common side effects
Ostale česte nuspojave
Other common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and in early treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.
Druge česte nuspojave (mogu se javiti u manje od 1 na 10 osoba) uključuju promjene u razinama nekih krvnih stanica i cirkulirajućih masnoća te, u ranim fazama liječenja, privremena povećanja razine jetrenih enzima; povećanja razine šećera u krvi i mokraći; povećanje razine mokraćne kiseline i kreatin fosfokinaze u krvi; osjećaj veće gladi; omaglicu; nemir; nevoljno drhtanje; neuobičajene pokrete (diskinezija); zatvor; suha usta; osip; gubitak snage; ekstremni umor; zadržavanje vode koje vodi do oticanja ruku, gležnjeva ili stopala; vrućicu; bol u zglobovima; i seksualnu disfunkciju kao što je smanjeni libido kod muškaraca i žena ili erektilnu disfunkciju kod muškaraca.
Other common side effects (seen in more than 1 in 10 patients) that have been observed with hydrochlorothiazide alone are hypokalaemia (low blood potassium levels) and increases in blood cholesterol and triglyceride (a type of fat) levels.
Druge česte nuspojave (kod više od 1 na 10 bolesnika) koje su uočene samo s hidroklorotiazidom su hipokalemija (niske razine kalija u krvi) i povišenje razina kolesterola i triglicerida (tipa masti) u krvi.
Other common side effects (seen in up to 1 patient in 10) are hypocalcaemia and hypophosphataemia (low levels of calcium or phosphate in the blood), excessive sweating, tooth loss and osteonecrosis in the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth).
Druge uobičajene nuspojave (mogu se javiti u više od 1 na 10 osoba) su hipokalkemija i hipofosfatemija (niske razine kalcija ili fosfata u krvi), prekomjerno znojenje, gubitak zubi i osteonekroza u čeljusti (oštećenje kosti u čeljusti koje može imati za posljedicu bolove, rane usne šupljine ili gubitak zubi).
Other common side effects are anaemia (low levels of red blood cells), rash and abnormal results in tests of liver function.
Druge česte nuspojave uključuju anemiju (niska razina crvenih krvnih stanica), osip i poremećaje jetrene funkcije.